CStone announces the GEMSTONE-302 study of sugemalimab met the endpoint of overall survival in the first-line treatment of metastatic non-small cell lung cancer patients

By In The News
January 19, 2022 in The Headlines

Followers 0

Recommended Posts

In The News

Posted January 19, 2022

- Share

Posted January 19, 2022

Sugemalimab is the world's first PD-L1 monoclonal antibody that when administered along with chemotherapy improved overall survival of first-line metastatic squamous and non-squamous non-small cell lung cancer patients in a statistically significant and clinically meaningful manner...

View the full article

Link to comment

Share on other sites

Create an account or sign in to comment

You need to be a member in order to leave a comment

Create an account

Sign in

Already have an account? Sign in here.

Followers 0

Go to topic listing

Most Contributions
1. In The News
  220060
2. Jaydee
  16865
3. Kip Powick
  12237
4. deicer
  12225
5. dagger
  9596
Tell a friend
Love The Airline Website? Tell a friend!
- Email
- Share
Forum Statistics
- Total Topics
  
  270.4k
- Total Posts
  
  559.2k

Sign In

CStone announces the GEMSTONE-302 study of sugemalimab met the endpoint of overall survival in the first-line treatment of metastatic non-small cell lung cancer patients

Recommended Posts

In The News

Link to comment

Share on other sites

Create an account or sign in to comment

Create an account

Sign in

Most Contributions

Tell a friend

Forum Statistics

Browse

Activity

Support